Bone Marrow Transplantation, ISSN 0268-3369, 08/2015, Volume 50, Issue 8, pp. 1013 - 1023
Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers, particularly beyond 5 years after HCT and...
LONG-TERM SURVIVORS | ORAL-CANCER | TESTICULAR CANCER | ADULTS | IMMUNOLOGY | TRANSPLANTATION | BREAST-CANCER | CHILDHOOD-CANCER | ONCOLOGY | INCREASED RISK | SKIN | HEMATOLOGY | MALIGNANT NEOPLASMS | BASAL-CELL | Mass Screening | Humans | Risk Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Male | Organ Specificity | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Transplantation | Diagnosis | Health aspects | Methods | Hematopoietic stem cells | Cancer
LONG-TERM SURVIVORS | ORAL-CANCER | TESTICULAR CANCER | ADULTS | IMMUNOLOGY | TRANSPLANTATION | BREAST-CANCER | CHILDHOOD-CANCER | ONCOLOGY | INCREASED RISK | SKIN | HEMATOLOGY | MALIGNANT NEOPLASMS | BASAL-CELL | Mass Screening | Humans | Risk Factors | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Male | Organ Specificity | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Transplantation | Diagnosis | Health aspects | Methods | Hematopoietic stem cells | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 4, pp. 335 - 347
This randomized, double-blind trial of prophylaxis to prevent invasive fungal infections was conducted in 600 patients with severe graft-versus-host disease...
CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | IN-VITRO ACTIVITIES | BONE-MARROW-TRANSPLANTATION | ANTIFUNGAL AGENTS | INVASIVE FUNGAL-INFECTIONS | AMPHOTERICIN-B | STEM-CELL TRANSPLANTATION | RECIPIENTS | ASPERGILLUS INFECTIONS | Mycoses - prevention & control | Triazoles - adverse effects | Antifungal Agents - adverse effects | Graft vs Host Disease - complications | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Fluconazole - adverse effects | Male | Opportunistic Infections - prevention & control | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Graft vs Host Disease - drug therapy | Aspergillosis - prevention & control | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Aged | Mycoses - mortality | Triazoles - therapeutic use | Mycoses | Dosage and administration | Fluconazole | Drug therapy | Fungi | Transplants & implants | Fungal infections
CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | RISK-FACTORS | IN-VITRO ACTIVITIES | BONE-MARROW-TRANSPLANTATION | ANTIFUNGAL AGENTS | INVASIVE FUNGAL-INFECTIONS | AMPHOTERICIN-B | STEM-CELL TRANSPLANTATION | RECIPIENTS | ASPERGILLUS INFECTIONS | Mycoses - prevention & control | Triazoles - adverse effects | Antifungal Agents - adverse effects | Graft vs Host Disease - complications | Double-Blind Method | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Fluconazole - adverse effects | Male | Opportunistic Infections - prevention & control | Fluconazole - therapeutic use | Antifungal Agents - therapeutic use | Graft vs Host Disease - drug therapy | Aspergillosis - prevention & control | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Aged | Mycoses - mortality | Triazoles - therapeutic use | Mycoses | Dosage and administration | Fluconazole | Drug therapy | Fungi | Transplants & implants | Fungal infections
Journal Article
Leukemia, ISSN 0887-6924, 12/2005, Volume 19, Issue 12, pp. 2304 - 2312
Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to...
Reduced intensity preparative regimen | Genmoidentical haematopoitic stem cell transplants | Acute myelocytic leukemia | MORTALITY | SURVIVAL | reduced intensity preparative regimen | UNRELATED DONORS | PREPARATIVE REGIMENS | ACUTE MYELOID-LEUKEMIA | genoidentical haematopoietic stem cell transplants | VERSUS-HOST-DISEASE | THERAPY | MORBIDITY | ONCOLOGY | acute myelocytic leukaemia | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Multivariate Analysis | Recurrence | Histocompatibility Testing | Humans | Middle Aged | Male | Treatment Outcome | Hematopoietic Stem Cell Transplantation - mortality | Cause of Death | Transplantation, Homologous | Dose-Response Relationship, Drug | Survival Analysis | Female | Registries | Aged | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Dose-Response Relationship, Radiation | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings
Reduced intensity preparative regimen | Genmoidentical haematopoitic stem cell transplants | Acute myelocytic leukemia | MORTALITY | SURVIVAL | reduced intensity preparative regimen | UNRELATED DONORS | PREPARATIVE REGIMENS | ACUTE MYELOID-LEUKEMIA | genoidentical haematopoietic stem cell transplants | VERSUS-HOST-DISEASE | THERAPY | MORBIDITY | ONCOLOGY | acute myelocytic leukaemia | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Multivariate Analysis | Recurrence | Histocompatibility Testing | Humans | Middle Aged | Male | Treatment Outcome | Hematopoietic Stem Cell Transplantation - mortality | Cause of Death | Transplantation, Homologous | Dose-Response Relationship, Drug | Survival Analysis | Female | Registries | Aged | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Dose-Response Relationship, Radiation | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 3, pp. 389 - 401.e1
Abstract The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic...
Hematology, Oncology and Palliative Medicine | Chronic graft-versus-host disease | National Institutes of Health | Diagnosis | Staging | National institutes of health | SURVIVAL | RISK-FACTORS | SCORE | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | NONRELAPSE MORTALITY | ORGAN | TRANSPLANTATION | CHRONIC GVHD CONSORTIUM | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | SEVERITY | Graft vs Host Disease - therapy | United States | Humans | Male | Graft vs Host Disease - metabolism | Organ Specificity | Consensus | Biomarkers | Consensus Development Conferences, NIH as Topic | Female | Clinical Trials as Topic - methods | Clinical Trials as Topic - standards | Chronic Disease | Graft vs Host Disease - diagnosis | Practice Guidelines as Topic | Clinical trials | Political corruption | Reports | diagnosis | NIH | staging | Chronic GVHD
Hematology, Oncology and Palliative Medicine | Chronic graft-versus-host disease | National Institutes of Health | Diagnosis | Staging | National institutes of health | SURVIVAL | RISK-FACTORS | SCORE | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | NONRELAPSE MORTALITY | ORGAN | TRANSPLANTATION | CHRONIC GVHD CONSORTIUM | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | SEVERITY | Graft vs Host Disease - therapy | United States | Humans | Male | Graft vs Host Disease - metabolism | Organ Specificity | Consensus | Biomarkers | Consensus Development Conferences, NIH as Topic | Female | Clinical Trials as Topic - methods | Clinical Trials as Topic - standards | Chronic Disease | Graft vs Host Disease - diagnosis | Practice Guidelines as Topic | Clinical trials | Political corruption | Reports | diagnosis | NIH | staging | Chronic GVHD
Journal Article
Leukemia, ISSN 0887-6924, 03/2017, Volume 31, Issue 3, pp. 654 - 662
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be curative, but is associated with significant morbidity and mortality. Chronic...
BIOMARKERS | DIAGNOSIS | GLOBULIN | ONCOLOGY | UNRELATED DONORS | PREVENTION | FOLLOW-UP | LEUKEMIA | HEMATOLOGY | VERSUS-HOST-DISEASE | CANCER | MASS-SPECTROMETRY | Humans | Middle Aged | Male | Graft vs Host Disease - metabolism | Transplantation, Homologous | Incidence | Young Adult | Peptides - metabolism | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Proteomics - methods | Odds Ratio | Graft vs Host Disease - diagnosis | Graft vs Host Disease - etiology | Severity of Illness Index | Reproducibility of Results | Proteome | Adolescent | Graft vs Host Disease - prevention & control | ROC Curve | Aged | Chronic Disease | Cluster Analysis | Cohort Studies | Transplantation | Research | Mass spectrometry | Health aspects | Mortality | Hematopoietic stem cells
BIOMARKERS | DIAGNOSIS | GLOBULIN | ONCOLOGY | UNRELATED DONORS | PREVENTION | FOLLOW-UP | LEUKEMIA | HEMATOLOGY | VERSUS-HOST-DISEASE | CANCER | MASS-SPECTROMETRY | Humans | Middle Aged | Male | Graft vs Host Disease - metabolism | Transplantation, Homologous | Incidence | Young Adult | Peptides - metabolism | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Proteomics - methods | Odds Ratio | Graft vs Host Disease - diagnosis | Graft vs Host Disease - etiology | Severity of Illness Index | Reproducibility of Results | Proteome | Adolescent | Graft vs Host Disease - prevention & control | ROC Curve | Aged | Chronic Disease | Cluster Analysis | Cohort Studies | Transplantation | Research | Mass spectrometry | Health aspects | Mortality | Hematopoietic stem cells
Journal Article
Leukemia, ISSN 0887-6924, 05/2011, Volume 25, Issue 5, pp. 808 - 813
Treatment options for adults with primary refractory acute myeloid leukaemia (PREF AML) are extremely limited. Although sibling allogeneic stem cell...
Primary refractory | acute myeloid leukaemia | unrelated donor transplantation | primary refractory | ONCOLOGY | HEMATOLOGY | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Survival Rate | Treatment Outcome | Living Donors | Remission Induction | Leukemia, Myeloid, Acute - mortality | Stem Cell Transplantation | Young Adult | Adolescent | Adult | Female | Aged | Leukemia, Myeloid, Acute - therapy | Chemotherapy | Transplantation | Research | Health aspects | Stem cells | Cancer
Primary refractory | acute myeloid leukaemia | unrelated donor transplantation | primary refractory | ONCOLOGY | HEMATOLOGY | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Survival Rate | Treatment Outcome | Living Donors | Remission Induction | Leukemia, Myeloid, Acute - mortality | Stem Cell Transplantation | Young Adult | Adolescent | Adult | Female | Aged | Leukemia, Myeloid, Acute - therapy | Chemotherapy | Transplantation | Research | Health aspects | Stem cells | Cancer
Journal Article
Leukemia, ISSN 0887-6924, 2014, Volume 28, Issue 4, pp. 842 - 852
Allogeneic hematopoietic stem cell transplantation is one curative treatment for hematological malignancies, but is compromised by life-threatening...
hematopoietic stem cell transplantation | mass spectrometry | proteomics | capillary electrophoresis | graft-versus-host disease | RISK-FACTORS | ACUTE GVHD | UNRELATED DONORS | FOLLOW-UP | MASS-SPECTROMETRY | BIOMARKERS | GLOBULIN | THERAPY | ONCOLOGY | ALBUMIN | HEMATOLOGY | APLASTIC-ANEMIA | Acute Disease | Humans | Middle Aged | Logistic Models | Male | Serum Albumin - analysis | Transplantation, Homologous | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Proteomics | Adult | Female | Aged | Graft vs Host Disease - urine | Graft vs Host Disease - diagnosis | Stem cell research | Graft versus host reaction | Transplantation | Research | Hematopoietic stem cells
hematopoietic stem cell transplantation | mass spectrometry | proteomics | capillary electrophoresis | graft-versus-host disease | RISK-FACTORS | ACUTE GVHD | UNRELATED DONORS | FOLLOW-UP | MASS-SPECTROMETRY | BIOMARKERS | GLOBULIN | THERAPY | ONCOLOGY | ALBUMIN | HEMATOLOGY | APLASTIC-ANEMIA | Acute Disease | Humans | Middle Aged | Logistic Models | Male | Serum Albumin - analysis | Transplantation, Homologous | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Proteomics | Adult | Female | Aged | Graft vs Host Disease - urine | Graft vs Host Disease - diagnosis | Stem cell research | Graft versus host reaction | Transplantation | Research | Hematopoietic stem cells
Journal Article
Leukemia, ISSN 0887-6924, 2004, Volume 18, Issue 6, pp. 1115 - 1121
The translocation t(8; 16)(p11; p13) is associated with acute myeloid leukemia displaying monocytic differentiation (AML FAB M4/5) and fuses the MOZ ( also...
AML | CBP | Minimal residual disease | MOZ | RT-PCR | ACUTE MYELOMONOCYTIC LEUKEMIA | TRANSLOCATION | FUSION TRANSCRIPT | HISTONE ACETYLTRANSFERASE | MLL | FUSES | GENE | ONCOLOGY | CREB-BINDING-PROTEIN | minimal residual disease | ACUTE MONOCYTIC LEUKEMIA | PATIENT | HEMATOLOGY | Neoplasm, Residual - pathology | Translocation, Genetic | Histone Acetyltransferases | Prognosis | Humans | Leukemia, Myeloid - genetics | Middle Aged | Male | Acetyltransferases - genetics | Leukemia, Myeloid - pathology | Monocytes - pathology | Trans-Activators - genetics | Adult | Female | Cell Differentiation | Nuclear Proteins - genetics | Acute Disease | Introns | CREB-Binding Protein | In Situ Hybridization, Fluorescence | Chromosomes, Human, Pair 8 | Reverse Transcriptase Polymerase Chain Reaction | Neoplasm, Residual - genetics | Adolescent | Chromosomes, Human, Pair 16 | Aged | Chimera
AML | CBP | Minimal residual disease | MOZ | RT-PCR | ACUTE MYELOMONOCYTIC LEUKEMIA | TRANSLOCATION | FUSION TRANSCRIPT | HISTONE ACETYLTRANSFERASE | MLL | FUSES | GENE | ONCOLOGY | CREB-BINDING-PROTEIN | minimal residual disease | ACUTE MONOCYTIC LEUKEMIA | PATIENT | HEMATOLOGY | Neoplasm, Residual - pathology | Translocation, Genetic | Histone Acetyltransferases | Prognosis | Humans | Leukemia, Myeloid - genetics | Middle Aged | Male | Acetyltransferases - genetics | Leukemia, Myeloid - pathology | Monocytes - pathology | Trans-Activators - genetics | Adult | Female | Cell Differentiation | Nuclear Proteins - genetics | Acute Disease | Introns | CREB-Binding Protein | In Situ Hybridization, Fluorescence | Chromosomes, Human, Pair 8 | Reverse Transcriptase Polymerase Chain Reaction | Neoplasm, Residual - genetics | Adolescent | Chromosomes, Human, Pair 16 | Aged | Chimera
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 06/2016, Volume 51, Issue 6, pp. 778 - 785
Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through...
EUROPE | PERSPECTIVE | ONCOLOGY | SCT | DONORS | IMMUNOLOGY | HEMATOLOGY | TRENDS | ORGAN-TRANSPLANTATION | TRANSPLANTATION | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Hematopoietic Stem Cell Transplantation - utilization | Humans | Bone Marrow Transplantation | Global Health - statistics & numerical data | Surveys and Questionnaires | Tissue Donors | Transplantation, Haploidentical | Peripheral Blood Stem Cell Transplantation | Transplantation, Homologous | Cord Blood Stem Cell Transplantation | Surveys | Health care industry | Forecasts and trends | Transplantation | Medical statistics | Hematopoietic stem cells | Usage | Analysis | Stem cells | Research | Data entry | emerging technologies | Non Governmental Organization | SWOT analysis | Worldwide Network for Blood and Marrow Transplantation WBMT | global | transplant rates | hematopoietic stem cell transplantation (HSCT) | haploidentical transplants | cord blood transplants | trends | WHO
EUROPE | PERSPECTIVE | ONCOLOGY | SCT | DONORS | IMMUNOLOGY | HEMATOLOGY | TRENDS | ORGAN-TRANSPLANTATION | TRANSPLANTATION | Hematopoietic Stem Cell Transplantation - statistics & numerical data | Hematopoietic Stem Cell Transplantation - utilization | Humans | Bone Marrow Transplantation | Global Health - statistics & numerical data | Surveys and Questionnaires | Tissue Donors | Transplantation, Haploidentical | Peripheral Blood Stem Cell Transplantation | Transplantation, Homologous | Cord Blood Stem Cell Transplantation | Surveys | Health care industry | Forecasts and trends | Transplantation | Medical statistics | Hematopoietic stem cells | Usage | Analysis | Stem cells | Research | Data entry | emerging technologies | Non Governmental Organization | SWOT analysis | Worldwide Network for Blood and Marrow Transplantation WBMT | global | transplant rates | hematopoietic stem cell transplantation (HSCT) | haploidentical transplants | cord blood transplants | trends | WHO
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 11/2015, Volume 50, Issue 11, pp. 1445 - 1452
Previous studies of non-histocompatibility leukocyte antigen (HLA) gene single-nucleotide polymorphisms (SNPs) on subgroups of patients undergoing allogeneic...
BONE-MARROW-TRANSPLANTATION | PROMOTER POLYMORPHISM | RECEPTOR | IMMUNOLOGY | VERSUS-HOST-DISEASE | GENE POLYMORPHISMS | CHRONIC MYELOID-LEUKEMIA | TRANSPLANTATION | IN-VITRO | MESSENGER-RNA | ONCOLOGY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ASSOCIATION | Haplotypes | Hematologic Neoplasms - therapy | Risk Assessment - methods | Multiple Organ Failure - mortality | Prognosis | Follow-Up Studies | Hematologic Neoplasms - mortality | Humans | Middle Aged | Receptors, Interleukin-1 - genetics | Male | Hematopoietic Stem Cell Transplantation - mortality | Cause of Death | Allografts | Graft vs Host Disease - mortality | Adult | Female | Transplantation Conditioning - adverse effects | Child | Interleukin-6 - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Genotype | Infection - mortality | Treatment Outcome | Membrane Glycoproteins - genetics | Estrogen Receptor alpha - genetics | Interleukin-10 - genetics | Adolescent | Aged | Polymorphism, Single Nucleotide | Histocompatibility | Histocompatibility antigens | Patient outcomes | HLA histocompatibility antigens | Genetic aspects | Transplantation | Single nucleotide polymorphisms | Health aspects | Risk factors | Hematopoietic stem cells | Methods | Graft rejection
BONE-MARROW-TRANSPLANTATION | PROMOTER POLYMORPHISM | RECEPTOR | IMMUNOLOGY | VERSUS-HOST-DISEASE | GENE POLYMORPHISMS | CHRONIC MYELOID-LEUKEMIA | TRANSPLANTATION | IN-VITRO | MESSENGER-RNA | ONCOLOGY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ASSOCIATION | Haplotypes | Hematologic Neoplasms - therapy | Risk Assessment - methods | Multiple Organ Failure - mortality | Prognosis | Follow-Up Studies | Hematologic Neoplasms - mortality | Humans | Middle Aged | Receptors, Interleukin-1 - genetics | Male | Hematopoietic Stem Cell Transplantation - mortality | Cause of Death | Allografts | Graft vs Host Disease - mortality | Adult | Female | Transplantation Conditioning - adverse effects | Child | Interleukin-6 - genetics | Kaplan-Meier Estimate | Proportional Hazards Models | Genotype | Infection - mortality | Treatment Outcome | Membrane Glycoproteins - genetics | Estrogen Receptor alpha - genetics | Interleukin-10 - genetics | Adolescent | Aged | Polymorphism, Single Nucleotide | Histocompatibility | Histocompatibility antigens | Patient outcomes | HLA histocompatibility antigens | Genetic aspects | Transplantation | Single nucleotide polymorphisms | Health aspects | Risk factors | Hematopoietic stem cells | Methods | Graft rejection
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 02/2013, Volume 48, Issue 2, pp. 220 - 225
The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic...
serious adverse reactions | WBMT | donor outcome | global donor follow-up | minimal data set | COLLECTION | RHG-CSF | EVENTS | COLONY-STIMULATING FACTOR | MOBILIZATION | UNRELATED DONORS | BONE-MARROW | IMMUNOLOGY | TRANSPLANTATION | HEALTHY DONORS | ONCOLOGY | LONG-TERM SAFETY | EXPERIENCE | HEMATOLOGY | Young Adult | Donor Selection | Hematopoietic Stem Cells - cytology | Humans | Middle Aged | Adolescent | Adult | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Transplantation, Homologous | Transplantation | Management | Health aspects | Donation of organs, tissues, etc | Hematopoietic stem cells | Side effects | Conferences | Donors | Risk assessment | Stem cells | Data processing | Blood | Hemopoiesis
serious adverse reactions | WBMT | donor outcome | global donor follow-up | minimal data set | COLLECTION | RHG-CSF | EVENTS | COLONY-STIMULATING FACTOR | MOBILIZATION | UNRELATED DONORS | BONE-MARROW | IMMUNOLOGY | TRANSPLANTATION | HEALTHY DONORS | ONCOLOGY | LONG-TERM SAFETY | EXPERIENCE | HEMATOLOGY | Young Adult | Donor Selection | Hematopoietic Stem Cells - cytology | Humans | Middle Aged | Adolescent | Adult | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Transplantation, Homologous | Transplantation | Management | Health aspects | Donation of organs, tissues, etc | Hematopoietic stem cells | Side effects | Conferences | Donors | Risk assessment | Stem cells | Data processing | Blood | Hemopoiesis
Journal Article